SCHEMBL827693

SCHEMBL827693

COC(=O)c1ccnc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 1/20 0.57
KDM4E B2RXH2 6/20 0.56
SLC40A1 Q9NP59 1/20 0.51
MAP2K1 Q02750 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 3/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 2/20 0.47
ATM Q13315 1/20 0.47
CYP3A4 P08684 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
PLIN1 O60240 1/20 0.47
GLA P06280 1/20 0.47
PKM P14618 1/20 0.47
MAPK1 P28482 1/20 0.47
PLIN5 Q00G26 1/20 0.47
MCL1 Q07820 1/20 0.47
ABHD5 Q8WTS1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL827213 0.88 KDM4E (0.59) PSMD14KDM4EMAP2K1MEN1KMT2A
SCHEMBL9318643 0.83 PABPC1 (0.44) PSMD14KDM4ESLC40A1MEN1KMT2A
SCHEMBL22169485 0.83 LMNA (0.44) PSMD14KDM4EALDH1A1LMNAHPGD
SCHEMBL28834556 0.82 HDAC3 (0.58) KDM4EALDH1A1LMNAHPGDCYP3A4
SCHEMBL28176881 0.82 LMNA (0.45) PSMD14MEN1KMT2AALDH1A1LMNA
SCHEMBL29523397 0.82 NUDT1 (0.57) KDM4EMEN1KMT2AALDH1A1POLB
SCHEMBL6824375 0.82 ALDH1A1 (0.47) PSMD14KDM4EMEN1KMT2AALDH1A1
SCHEMBL1768671 0.82 NUDT1 (0.57) KDM4EMEN1KMT2AALDH1A1POLB
SCHEMBL21056849 0.81 SLC22A12 (0.54) PSMD14KDM4ESLC40A1MAP2K1KMT2A
SCHEMBL16131035 0.81 NR4A2 (0.51) PSMD14KDM4ESLC40A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
CN-119954810-A Regulator of fused ring derivative, preparation method and application thereof 上海翰森生物医药科技有限公司 2025-05-09 CN disclosed
EP-4543869-A1 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES Astrazeneca AB (SE) 2025-04-30 EP disclosed
CN-119562951-A N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide 阿斯利康(瑞典)有限公司 2025-03-04 CN disclosed
EP-3630770-B1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS RELAY THERAPEUTICS INC (US) 2024-08-28 EP disclosed
WO-2023247488-A1 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2023-12-28 WO disclosed
CN-117247351-A Method for synthesizing nitrogen-containing heteroarene carboxylic acid compound based on hydrocarbon bond carboxylation reaction of nitrogen-containing heteroarene 四川大学 2023-12-19 CN disclosed
EP-4276533-A1 CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION AND RESIST PATTERN FORMING PROCESS Shin-Etsu Chemical Co., Ltd. (JP) 2023-11-15 EP disclosed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 EP disclosed
CN-116745291-A N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide 阿斯利康(瑞典)有限公司 2023-09-12 CN disclosed
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2005-07-07 US disclosed
EP-1481978-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST Mitsubishi Rayon Co., Ltd. (JP) 2004-12-01 EP disclosed
US-6410529-B1 DIETETICS; NON-INSULIN DEPENDENT DIABETES; SLEEP DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2002-06-25 US disclosed
EP-1003737-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2000-05-31 EP disclosed
EP-0922044-A1 PYRROLO(3,2-C) QUINOLINE DERIVATIVES PHARMACIA & UPJOHN S.p.A. (IT) 1999-06-16 EP disclosed
WO-1999009024-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1999-02-25 WO disclosed
WO-1998005660-A1 PYRROLO(3,2-C) QUINOLINE DERIVATIVES PHARMACIA & UPJOHN S.P.A. (IT) 1998-02-12 WO disclosed
US-5071987-A Quinoline dyes; colorfastness BASF AKTIENGESELLSCHAFT (DE) 1991-12-10 US disclosed
US-4968803-A FLUORINE AS OXIDANT ALLIED-SIGNAL INC. (US) 1990-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst PIN4, IPO5, HLCS PSMD14 2852/4885KDM4E 2745/4885SLC40A1 3940/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR PSMD14 3560/4885KDM4E 3646/4885SLC40A1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.